Inventor
PHUAPRADIT WANTANEE
US58 patents
⚠️ This page may combine multiple inventors who share the name “PHUAPRADIT WANTANEE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
KASHIV SPECIALTY PHARMACEUTICALS LLC
13 patentsUS11179320B2Nov 23, 2021
Self-regulating osmotic gastroretentive drug delivery systems
KASHIV SPECIALTY PHARMACEUTICALS LLC3 citations83
US11000471B2May 11, 2021
Programmable pharmaceutical compositions for chrono drug release
KASHIV SPECIALTY PHARMACEUTICALS LLC3 citations83
US10980738B2Apr 20, 2021
Programmable pharmaceutical compositions for chrono drug release
KASHIV SPECIALTY PHARMACEUTICALS LLC5 citations83
US11478425B2Oct 25, 2022
Extended release compositions comprising pyridostigmine
KASHIV SPECIALTY PHARMACEUTICALS LLC2 citations73
US11154505B1Oct 26, 2021
Extended release compositions comprising trihexyphenidyl
KASHIV SPECIALTY PHARMACEUTICALS LLC3 citations73
US11045420B2Jun 29, 2021
Extended release compositions comprising trihexyphenidyl
KASHIV SPECIALTY PHARMACEUTICALS LLC4 citations73
US11040014B2Jun 22, 2021
Extended release compositions comprising trihexyphenidyl
KASHIV SPECIALTY PHARMACEUTICALS LLC4 citations73
US10925833B2Feb 23, 2021
Extended release compositions comprising pyridostigmine
KASHIV SPECIALTY PHARMACEUTICALS LLC2 citations73
US10881617B1Jan 5, 2021
Extended release compositions comprising pyridostigmine
KASHIV SPECIALTY PHARMACEUTICALS LLC2 citations73
US11154494B2Oct 26, 2021
Programmable pharmaceutical compositions for chrono drug release
KASHIV SPECIALTY PHARMACEUTICALS LLC1 citations72
US10952957B2Mar 23, 2021
Self-regulating osmotic gastroretentive drug delivery systems
KASHIV SPECIALTY PHARMACEUTICALS LLC2 citations72
US11007145B2May 18, 2021
Gastroretentive dosage forms for sustained drug delivery
KASHIV SPECIALTY PHARMACEUTICALS LLC1 citations71
US11564888B2Jan 31, 2023
Extended release compositions comprising trihexyphenidyl
KASHIV SPECIALTY PHARMACEUTICALS LLC0 citations62
KASHIV BIOSCIENCES LLC
12 patentsUS10869839B2Dec 22, 2020
Extended release compositions comprising trihexyphenidyl
KASHIV BIOSCIENCES LLC5 citations84
US10898430B2Jan 26, 2021
Self-regulating osmotic gastroretentive drug delivery systems
KASHIV BIOSCIENCES LLC5 citations83
US10898431B2Jan 26, 2021
Programmable pharmaceutical compositions for chrono drug release
KASHIV BIOSCIENCES LLC8 citations83
US10849846B2Dec 1, 2020
Self-regulating osmotic gastroretentive drug delivery systems
KASHIV BIOSCIENCES LLC6 citations83
US10744083B2Aug 18, 2020
Self-regulating osmotic gastroretentive drug delivery systems
KASHIV BIOSCIENCES LLC6 citations83
US11229606B2Jan 25, 2022
Extended release compositions comprising pyridostigmine
KASHIV BIOSCIENCES LLC1 citations73
US10987311B2Apr 27, 2021
Extended release compositions comprising pyridostigmine
KASHIV BIOSCIENCES LLC2 citations73
US10744093B2Aug 18, 2020
Extended release compositions comprising pyridostigmine
KASHIV BIOSCIENCES LLC2 citations73
US10588863B2Mar 17, 2020
Extended release compositions comprising pyridostigmine
KASHIV BIOSCIENCES LLC2 citations73
US10406234B2Sep 10, 2019
Method of manufacturing fine particles suitable for orally disintegrating pharmaceutical dosage forms
KASHIV BIOSCIENCES LLC2 citations73
US10857098B2Dec 8, 2020
Gastroretentive dosage forms for sustained drug delivery
KASHIV BIOSCIENCES LLC1 citations71
US10500282B2Dec 10, 2019
Supersaturated stabilized nanoparticles for poorly soluble drugs
KASHIV BIOSCIENCES LLC2 citations71
AMNEAL COMPLEX PRODUCTS RES LLC
12 patentsUS11166906B2Nov 9, 2021
Programmable pharmaceutical compositions for chrono drug release
AMNEAL COMPLEX PRODUCTS RES LLC3 citations83
US11793747B2Oct 24, 2023
Self-regulating osmotic gastroretentive drug delivery systems
AMNEAL COMPLEX PRODUCTS RES LLC1 citations72
US11684580B2Jun 27, 2023
Extended release compositions comprising trihexyphenidyl
AMNEAL COMPLEX PRODUCTS RES LLC1 citations72
US11666536B2Jun 6, 2023
Extended release compositions comprising pyridostigmine
AMNEAL COMPLEX PRODUCTS RES LLC1 citations72
US11464742B2Oct 11, 2022
Extended release compositions comprising trihexyphenidyl
AMNEAL COMPLEX PRODUCTS RES LLC1 citations72
US11419813B2Aug 23, 2022
Programmable pharmaceutical compositions for chrono drug release
AMNEAL COMPLEX PRODUCTS RES LLC1 citations72
US11318091B2May 3, 2022
Gastroretentive dosage forms for sustained drug delivery
AMNEAL COMPLEX PRODUCTS RES LLC1 citations71
US12233166B2Feb 25, 2025
Extended release compositions comprising pyridostigmine
AMNEAL COMPLEX PRODUCTS RES LLC0 citations62
US11964048B2Apr 23, 2024
Sustained release compositions comprising liothyronine
AMNEAL COMPLEX PRODUCTS RES LLC1 citations62
US11911515B2Feb 27, 2024
Extended release compositions comprising pyridostigmine
AMNEAL COMPLEX PRODUCTS RES LLC0 citations62
US11439585B2Sep 13, 2022
Programmable pharmaceutical compositions for chrono drug release
AMNEAL COMPLEX PRODUCTS RES LLC0 citations61
US12042559B2Jul 23, 2024
Gastroretentive dosage forms for sustained drug delivery
AMNEAL COMPLEX PRODUCTS RES LLC0 citations59
HOFFMANN LA ROCHE
9 patentsUS7014866B2Mar 21, 2006
High dose solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate and process for making same
HOFFMANN LA ROCHE151 citations98
US6350786B1Feb 26, 2002
Stable complexes of poorly soluble compounds in ionic polymers
HOFFMANN LA ROCHE94 citations96
US6039975AMar 21, 2000
Colon targeted delivery system
HOFFMANN LA ROCHE522 citations96
US5482718AJan 9, 1996
Colon-targeted delivery system
HOFFMANN LA ROCHE66 citations93
US5393765AFeb 28, 1995
Pharmaceutical compositions with constant erosion volume for zero order controlled release
HOFFMANN LA ROCHE92 citations93
US6486329B1Nov 26, 2002
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
HOFFMANN LA ROCHE10 citations72
US6492530B1Dec 10, 2002
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
HOFFMANN LA ROCHE2 citations61
US6482847B2Nov 19, 2002
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
HOFFMANN LA ROCHE1 citations61
US6469179B1Oct 22, 2002
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
HOFFMANN LA ROCHE2 citations61
KASHIV PHARMA LLC
3 patentsUS10918597B2Feb 16, 2021
Gastroretentive dosage forms for sustained drug delivery
KASHIV PHARMA LLC1 citations71
US9511078B2Dec 6, 2016
Self-nanoemulsion of poorly soluble drugs
KASHIV PHARMA LLC4 citations70
US10195150B2Feb 5, 2019
Orally disintegrating tablet formulation for enhanced bioavailability
KASHIV PHARMA LLC4 citations64
AHMED HASHIM A
1 patentShowing the top 50 of 58 patents by PatentIndex Score.